Trazodone and Rosuvastatin Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Comes Up So Often

Trazodone and rosuvastatin are two of the most frequently prescribed medications in the United States, and the overlap in patient populations makes co-prescribing common. Among adults aged 50 and older, depression and dyslipidemia frequently coexist, and trazodone's off-label use for insomnia adds another layer of prescribing volume.

According to the 2022 IQVIA National Prescription Audit, trazodone ranked among the top 25 most dispensed medications in the U.S., with over 30 million prescriptions filled annually. Rosuvastatin (brand name Crestor) similarly ranks in the top 10 by prescription volume. The probability that a single patient receives both drugs is high enough that the interaction question deserves a clear, evidence-based answer.

Patients searching for this interaction are often prompted by pharmacy software alerts. Many drug interaction checkers flag this pair at a low or informational level, which can generate anxiety without providing clinical context. The short answer: these two medications do not share the metabolic pathways that produce clinically dangerous statin-drug interactions [1].

Pharmacokinetic Profiles: Where These Drugs Do (and Don't) Overlap

Understanding why trazodone and rosuvastatin are a low-risk pair requires examining how each drug moves through the body. The metabolic separation between them is the central reason the combination is well tolerated.

Trazodone is extensively metabolized by cytochrome P450 3A4 (CYP3A4) in the liver. CYP2D6 contributes as a secondary pathway. The drug is converted to its primary active metabolite, meta-chlorophenylpiperazine (mCPP), which has serotonergic activity of its own. Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase trazodone exposure substantially, while CYP3A4 inducers (carbamazepine) reduce it [2].

Rosuvastatin stands apart from most other statins in one clinically important way. It is not meaningfully metabolized by CYP3A4. The FDA-approved label for rosuvastatin confirms that approximately 90% of an oral dose is eliminated unchanged, primarily through biliary excretion. CYP2C9 handles a minor fraction of its metabolism, and CYP2C19 contributes marginally [3]. This pharmacokinetic profile is precisely why rosuvastatin avoids the interaction risks that plague atorvastatin, lovastatin, and simvastatin when combined with CYP3A4-active drugs.

Hepatic uptake of rosuvastatin depends on organic anion transporting polypeptides OATP1B1 and OATP1B3, along with the efflux transporter BCRP (breast cancer resistance protein). Drugs that inhibit these transporters (cyclosporine, certain protease inhibitors) can sharply increase rosuvastatin plasma concentrations and raise myopathy risk [4]. Trazodone has no established inhibitory activity against OATP1B1, OATP1B3, or BCRP based on currently published in vitro and clinical data.

The net result: no shared CYP450 competition, no transporter inhibition, no expected change in the plasma levels of either drug.

How Rosuvastatin Differs From CYP3A4-Dependent Statins

This distinction matters. Not all statins behave the same way, and the interaction profile of rosuvastatin is categorically different from that of simvastatin or lovastatin.

Simvastatin and lovastatin are prodrugs converted to active hydroxy acid forms by CYP3A4. When a CYP3A4 substrate or inhibitor is added, their plasma levels can increase by 2- to 10-fold, driving the risk of rhabdomyolysis [5]. The FDA simvastatin label includes specific contraindications and dose caps with CYP3A4 inhibitors for this reason. Atorvastatin is also a CYP3A4 substrate, though its interaction sensitivity is somewhat lower than simvastatin's.

Rosuvastatin sidesteps this entire problem. A 2003 pharmacokinetic study published in Clinical Pharmacology & Therapeutics demonstrated that co-administration with the strong CYP3A4 inhibitor itraconazole did not alter rosuvastatin AUC or Cmax [6]. This finding has been replicated across multiple interaction studies and confirms that trazodone, as a CYP3A4 substrate (not a potent inhibitor), poses no meaningful pharmacokinetic threat to rosuvastatin clearance.

For patients already taking trazodone who need statin therapy, or vice versa, rosuvastatin may actually represent a preferred choice within the statin class specifically because of this metabolic independence.

Pharmacodynamic Considerations: What to Watch For

Although the pharmacokinetic interaction risk is low, pharmacodynamic monitoring remains appropriate when combining any two systemic medications.

Orthostatic hypotension. Trazodone causes dose-related alpha-1 adrenergic blockade, which can produce orthostatic hypotension, particularly during the first weeks of therapy or with dose increases [7]. Rosuvastatin does not directly lower blood pressure, but many patients taking a statin are also on antihypertensives. The additive burden of multiple blood-pressure-lowering effects can increase fall risk, especially in adults over 65. The American Geriatrics Society 2023 Beers Criteria flags trazodone as a drug requiring fall-risk assessment in older adults.

Myalgia and musculoskeletal symptoms. Statin-associated muscle symptoms (SAMS) occur in 5% to 10% of statin users in observational studies, though the SAMSON trial (N=60) demonstrated that a large share of reported muscle symptoms are attributable to the nocebo effect [8]. Trazodone is not known to cause myopathy independently. There is no pharmacologic reason to expect trazodone to amplify statin myotoxicity, but patients should be counseled to report new-onset muscle pain, weakness, or dark urine regardless of their drug regimen.

QT interval. Trazodone carries a dose-dependent risk of QT prolongation, documented in the FDA trazodone label and in post-marketing cardiac safety data [9]. Rosuvastatin is not associated with QT prolongation. This pair does not compound QT risk in the way that, for example, trazodone combined with citalopram or ondansetron might. An ECG at baseline is reasonable for patients on trazodone doses exceeding 300 mg/day, but rosuvastatin co-administration does not change that threshold.

Hepatic function. Both trazodone and rosuvastatin undergo hepatic processing. The 2018 ACC/AHA cholesterol guideline no longer recommends routine liver function test monitoring for statin therapy in the absence of symptoms, though baseline hepatic panel assessment before initiating either drug remains reasonable practice [10]. In patients with pre-existing liver disease (Child-Pugh B or C), rosuvastatin is contraindicated at higher doses, and trazodone clearance may be prolonged. Hepatic impairment is the one clinical scenario where closer monitoring of this combination is warranted.

Drug Interaction Databases: What the Major Platforms Say

Clinicians and pharmacists frequently consult structured drug interaction databases before dispensing this combination. The major platforms agree on the classification.

Lexicomp categorizes trazodone plus rosuvastatin as a "monitor" interaction (Category C), meaning the combination may be used with appropriate surveillance but does not require dose changes or avoidance. The listed concern relates to general CNS effects and orthostatic hypotension rather than metabolic competition [11].

Micromedex assigns a similar low-severity rating. The Clinical Pharmacology database does not flag this pair as clinically significant. The Drugs.com interaction checker returns a "minor" interaction classification, advising patients to report dizziness or lightheadedness but not to discontinue either medication.

These consensus ratings reflect the pharmacokinetic reality. No case reports of rhabdomyolysis, serotonin syndrome, or other serious adverse events attributable specifically to the trazodone-rosuvastatin combination appear in the published literature as of May 2026.

Dosing Guidance and Clinical Recommendations

No dose adjustment of either trazodone or rosuvastatin is required when the two drugs are combined under standard prescribing conditions. The following recommendations apply.

Starting trazodone in a patient already on rosuvastatin: Begin trazodone at the standard initial dose (150 mg/day in divided doses for depression, or 25 to 100 mg at bedtime for insomnia). No rosuvastatin dose modification is needed. Counsel the patient about trazodone-specific side effects (sedation, orthostatic hypotension, priapism risk in men).

Starting rosuvastatin in a patient already on trazodone: Initiate rosuvastatin per the 2018 ACC/AHA guideline recommendations based on ASCVD risk. Typical starting doses range from 5 to 20 mg daily. No trazodone dose modification is needed [10].

Titration: Either drug can be titrated independently. Rosuvastatin can be increased to 40 mg/day (the maximum approved dose) without interaction concerns related to trazodone. Trazodone can be titrated to 400 mg/day for depression (or higher in some clinical scenarios) without pharmacokinetic implications for rosuvastatin.

Monitoring schedule: Check a lipid panel 4 to 12 weeks after starting or adjusting rosuvastatin. Assess trazodone efficacy and tolerability at 2- to 4-week intervals during titration. Baseline hepatic panel before initiating either drug. CK measurement only if the patient develops muscle symptoms.

When to reconsider the combination: If a patient on trazodone and rosuvastatin develops unexplained hepatic transaminase elevation exceeding 3 times the upper limit of normal, evaluate both drugs as potential contributors. If the patient is started on a strong CYP3A4 inhibitor (e.g., ketoconazole, clarithromycin, ritonavir), trazodone exposure may increase substantially, and the clinical picture changes, but rosuvastatin remains unaffected by that third-drug addition.

Special Populations

Older adults (age 65+). This is the population most likely to take both drugs simultaneously. Age-related reductions in hepatic blood flow and CYP activity can modestly increase trazodone exposure. The American Geriatrics Society recommends starting trazodone at the lowest effective dose in older adults and monitoring for excessive sedation and falls [12]. Rosuvastatin pharmacokinetics are not dramatically altered by age alone, though the 40 mg dose is used cautiously in this group. The combination remains appropriate with standard geriatric prescribing caution.

Renal impairment. Rosuvastatin exposure increases in severe renal impairment (GFR <30 mL/min), and the FDA label recommends a starting dose of 5 mg with a maximum of 10 mg in this population [3]. Trazodone is minimally renally cleared. No interaction-specific adjustment is needed, but the rosuvastatin dose cap applies regardless.

Hepatic impairment. Both drugs warrant caution. Rosuvastatin is contraindicated in active liver disease. Trazodone clearance decreases with hepatic dysfunction. In patients with compensated chronic liver disease, use the lowest effective doses of both drugs and monitor liver enzymes more frequently.

Pregnancy. Rosuvastatin is contraindicated in pregnancy. Trazodone is FDA pregnancy category C. This combination should not be used in pregnant patients due to the statin contraindication.

When Statin Choice Matters: Avoiding Problematic Combinations With Trazodone

For prescribers selecting a statin for a patient already on trazodone, the metabolic pathway is the deciding factor. Rosuvastatin and pravastatin are the two statins with the least CYP3A4 involvement, making them the preferred options when a CYP3A4-metabolized drug is already on board.

A 2012 review in Pharmacotherapy evaluated statin drug interaction profiles and concluded that rosuvastatin and pravastatin had the lowest interaction potential among the available statins, specifically because of their independence from CYP3A4 metabolism [13]. Pitavastatin, metabolized primarily through glucuronidation, represents another low-interaction option.

In contrast, combining trazodone with simvastatin or lovastatin does not create a direct interaction (trazodone is a CYP3A4 substrate, not a strong inhibitor), but it creates a prescribing environment where adding a third CYP3A4-active drug could simultaneously increase both trazodone and statin exposure. Choosing rosuvastatin eliminates this "stack risk."

Patient Counseling Points

For patients taking trazodone and rosuvastatin together, five counseling points are most relevant.

Take rosuvastatin at any consistent time of day (it has a long half-life and does not require evening dosing). Take trazodone at bedtime if using it for insomnia, or in divided doses if treating depression. Rise slowly from sitting or lying positions during the first weeks on trazodone, especially if you also take blood pressure medications. Report unexplained muscle pain, tenderness, or weakness to your prescriber (this relates to the statin, not the interaction). Do not stop either medication without consulting your clinician, as abrupt trazodone discontinuation can cause withdrawal symptoms and statin discontinuation raises cardiovascular risk.

Baseline CK is 38 to 174 U/L for men and 26 to 140 U/L for women; values exceeding 10 times the upper limit alongside symptoms warrant urgent evaluation and statin discontinuation [10].